Galena Biopharma, Inc. is a biopharmaceutical company developing hematology and oncology therapeutics that address unmet medical needs. The Company’s pipeline consists of multiple mid- to late-stage clinical assets, including our hematology asset, GALE-401, and our novel cancer immunotherapy programs including NeuVax (nelipepimut-S), GALE-301 and GALE-302. GALE-401 is a controlled release version of the approved drug anagrelide for the treatment of elevated platelets in patients with myeloproliferative neoplasms. GALE- 401 has completed a Phase 2 clinical trial and the asset is ready to advance into a pivotal trial in patients with essential thrombocythemia. NeuVax is currently in multiple investigator-sponsored Phase 2 clinical trials in breast cancer. GALE-301 and GALE-302 have completed early stage trials in ovarian, endometrial and breast cancers.

Type
Public
HQ
Portland, US
Founded
2003
Size (employees)
14 (est)
Galena Biopharma was founded in 2003 and is headquartered in Portland, US
Report incorrect company information

Galena Biopharma Office Locations

Galena Biopharma has an office in Portland
Portland, US (HQ)
270 4640 SW Macadam Ave
Show all (1)
Report incorrect company information

Galena Biopharma Financials and Metrics

Galena Biopharma Financials

USD

Net income (Q1, 2018)

(8 m)

Market capitalization (22-Dec-2017)

11.1 m

Cash (31-Mar-2018)

3.5 m

EV

17.3 m
Galena Biopharma's current market capitalization is $11.1 m.
Annual
USDFY, 2016FY, 2017

General and administrative expense

12 m15.1 m

R&D expense

19.9 m6.1 m

Operating expense total

31.9 m21.2 m

EBIT

(31.9 m)
Quarterly
USDQ3, 2014Q1, 2015Q2, 2016Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Revenue

1.6 m2.8 m3.4 m

Cost of goods sold

247 k393 k468 k

Gross profit

1.4 m2.4 m2.9 m

Gross profit Margin, %

85%86%86%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

47.8 m23.7 m29.7 m18.1 m2.3 m

Accounts Receivable

Inventories

386 k655 k581 k

Current Assets

53.5 m29 m53.6 m37.5 m13.1 m
Quarterly
USDQ3, 2014Q1, 2015Q2, 2016Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Cash

24.6 m52.9 m34.8 m34.7 m19.6 m24.5 m27.6 m3.5 m

Accounts Receivable

1.1 m1.8 m

Inventories

450 k637 k1.4 m

Current Assets

28.5 m57.3 m54.2 m37.9 m45.3 m44.5 m42 m13.1 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(76.7 m)(36.6 m)(63.9 m)(23.5 m)(23.8 m)

Inventories

Accounts Payable

8.4 m

Cash From Operating Activities

(11 m)
Quarterly
USDQ3, 2014Q1, 2015Q2, 2016Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Net Income

(6.2 m)(10.5 m)(18 m)(16.5 m)5.4 m(6.9 m)(11.7 m)(8 m)

Inventories

450 k637 k1.4 m

Accounts Payable

3.4 m3.3 m1.2 m1 m1.3 m894 k1.2 m(240 k)

Cash From Operating Activities

(5.4 m)
USDY, 2018

EV/CFO

-3.2 x

Financial Leverage

-25.4 x
Show all financial metrics
Report incorrect company information